{
    "clinical_study": {
        "@rank": "66987", 
        "arm_group": [
            {
                "arm_group_label": "IQP-LH-101 tablet", 
                "arm_group_type": "Active Comparator", 
                "description": "4 chewable tablets to be chewed thoroughly before swallowing"
            }, 
            {
                "arm_group_label": "IQP-LH-101 liquid", 
                "arm_group_type": "Active Comparator", 
                "description": "2 liquid sachets to be emptied into the mouth and consumed."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "1 tablet to be swallowed with water."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is a randomized, placebo-controlled, single-blind, three-way crossover clinical\n      trial to evaluate safety and efficacy of IQP-LH-101 (tablet form and liquid form) in\n      postprandial heartburn.\n\n      The null hypothesis is that there is no difference between IQP-LH-101 and the placebo in\n      terms of efficacy for postprandial heartburn treatment."
        }, 
        "brief_title": "Safety and Efficacy of IQP-LH-101 in Postprandial Heartburn", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": "Postprandial Heartburn", 
        "condition_browse": {
            "mesh_term": "Heartburn"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Post-prandial heartburn (e.g. after a high-fat meal) in at least 2 months prior to\n             the study (at least 2 times a week)\n\n          -  Not receiving prescribed treatment for heartburn, reflux or upper gastrointestinal\n             disorders\n\n          -  Written informed consent is a prerequisite for subject enrollment.\n\n        Exclusion Criteria:\n\n          -  Gastrointestinal bleeding within 12 months prior to the study\n\n          -  Difficulty swallowing (dysphagia)\n\n          -  History of or symptoms suggestive of Zollinger-Ellison syndrome, oesophageal or\n             gastric malignancy, gastric or duodenal ulcer, pernicious anaemia, Barrett's\n             oesophagus or systemic sclerosis\n\n          -  Participation in other studies within the last 30 days prior to entry or during the\n             study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "41", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01718639", 
            "org_study_id": "INQ/012512"
        }, 
        "intervention": [
            {
                "arm_group_label": "IQP-LH-101 tablet", 
                "description": "Oral medical device in the form of a chewable tablet", 
                "intervention_name": "IQP-LH-101 tablet", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "IQP-LH-101 liquid", 
                "description": "Oral medical device in the form of a liquid", 
                "intervention_name": "IQP-LH-101 liquid", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 7, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Berlin", 
                    "country": "Germany", 
                    "zip": "10369"
                }, 
                "name": "Wei\u00dfenseerweg 111"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "3", 
        "official_title": "Randomized, Controlled, Single-blind, Three-way Crossover Clinical Investigation to Evaluate Safety and Efficacy of IQP-LH-101 in Postprandial Heartburn", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The subject will be provided with a stopwatch started by the study staff at the time of investigational product application", 
            "measure": "Difference in time to both onset of soothing and onset of cooling after intake of investigational product between study arms", 
            "safety_issue": "No", 
            "time_frame": "Measured up to 30 minutes"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01718639"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The subject will be instructed to stop the stopwatch provided at first perception of recurring heartburn symptoms.", 
                "measure": "Duration of time until the first perception of recurring heartburn symptoms after intake of investigational product", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 hours"
            }, 
            {
                "description": "The subjects evaluate the efficacy of the device under investigation (global scaled eval-uation with \"very good\", \"good\", \"moderate\" and \"poor\").", 
                "measure": "Evaluation of efficacy", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 hours per crossover"
            }, 
            {
                "description": "The investigator will assess and document in the CRF any adverse events, device effects and device deficiencies.", 
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 4 weeks"
            }
        ], 
        "source": "InQpharm Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "InQpharm Group", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}